Davina Biel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Davina Biel has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Nicolai Franzmeier
Institute for Stroke and Dementia Research, University Hospital, LMU Munich Germany
18 shared publications - Sebastian Niclas Roemer
Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany
13 shared publications - Amir Dehsarvi
Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany
12 shared publications - Anna Steward
Institute for Stroke and Dementia Research (ISD), University Hospital, LMU, Munich Germany
12 shared publications - Anna Dewenter
Institute for Stroke and Dementia Research (ISD), University Hospital, LMU, Munich, Bavaria Germany
11 shared publications Fabian Wanger
Institute for Stroke and Dementia Research (ISD), University Hospital, LMU, Munich Germany
10 shared publications
Latest Publications
- 18 December 2025
- Published by Oxford University Press (OUP) in Brain
- Vol. 149 (6) , 1902-1914
ApoE4 lowers the ptau217 threshold for tau aggregation and spread in an allele dose-dependent manner
In Alzheimer’s disease, carriage of the apolipoprotein E ε4 (ApoE4) risk allele is linked to faster tau accumulation at lower amyloid-PET levels, thereby accelerating disease progression. However, it remains unclear whether this ApoE4-facilitated transition from amyloidosis to tauopathy is mechanistically promoted by increased secretion of phosphorylated tau (ptau), a key intermediate that drives the amyloid-to-tauopathy transition, or alternatively by increased ptau-driven tau aggregation. Therefore, we investigated where along the amyloid-to-tau axis ApoE4 accelerates tau aggregation and assessed: (i) whether ApoE4 increases ptau secretion; or (ii) whether ApoE4 increases ptau-associated tau aggregation. To this end, we analysed two large-scale APOE-genotyped cohorts covering the full Alzheimer’s disease spectrum (Alzheimer’s Disease Neuroimaging Initiative; ADNI: n = 201) as well as a preclinical cohort (Anti-Amyloid Treatment in Asymptomatic Alzheimer’s and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration study; A4-LEARN: n = 200), integrating baseline amyloid-PET, plasma ptau217 and CSF ptau181 with longitudinal tau-PET. Using linear regression, we tested whether ApoE4 carriage moderates: (i) amyloid-PET-associated plasma ptau217 increases; or (ii) ptau217-associated tau spreading from local epicentres across patient-tailored tau spreading stages. All analyses were independently validated across both cohorts, including an additional replication in an ADNI subset (n = 115) with available CSF ptau181 measures as an alternative marker of ptau secretion. Finally, we used logistic regression to determine ApoE4 allele count-stratified plasma ptau217 thresholds marking early pathological tau-PET increases. We found that ApoE4 did not facilitate amyloid-PET-associated ptau increases, suggesting that amyloid-related ptau secretion is not altered by ApoE4 carriage. Contrastingly, we found that plasma ptau217 elevations were linked to faster tau-PET spread from local epicentres across connected brain regions in an ApoE4 allele dose-dependent manner, independent of amyloid [ADNI/A4-LEARN: mean standardized beta (β) = 0.44/0.56, P < 0.001/P < 0.001]. Lastly, we found that a higher ApoE4 allele count was linked to lower ptau217 thresholds marking transition to tauopathy, i.e. early abnormal tau-PET increases, consistently across both samples (ADNI: 0/1/2 ApoE4 alleles = 0.62/0.34/0.15 pg/ml, representing ∼45% and ∼76% reductions from non-carriers; Fujirebio ptau217 assay; A4-LEARN: 0/1/2 ApoE4 alleles = 0.31/0.23/0.18 pg/ml, representing ∼26% and ∼42% reductions; Eli Lilly ptau217 assay). These findings suggest that ApoE4, i.e. the key genetic risk factor for sporadic Alzheimer’s disease, facilitates amyloid-dependent tau aggregation in an allele dose-dependent manner by enhancing the ptau-driven spread of fibrillar tau, leading to an earlier transition from amyloidosis to tauopathy at lower ptau217 levels. This has implications for plasma ptau-based screening approaches and therapeutic timing of anti-amyloid drugs in ApoE4 carriers. Specifically, ApoE4 carriers may require genotype-adjusted ptau thresholds to detect Alzheimer’s disease pathophysiology, as well as anti-amyloid treatment at lower ptau levels to prevent the transition to tauopathy, which ultimately drives neurodegeneration and cognitive decline.
- 18 December 2025
- Published by Oxford University Press (OUP) in Brain
- Vol. 149 (6) , 1902-1914
ApoE4 lowers the ptau217 threshold for tau aggregation and spread in an allele dose-dependent manner
In Alzheimer’s disease, carriage of the apolipoprotein E ε4 (ApoE4) risk allele is linked to faster tau accumulation at lower amyloid-PET levels, thereby accelerating disease progression. However, it remains unclear whether this ApoE4-facilitated transition from amyloidosis to tauopathy is mechanistically promoted by increased secretion of phosphorylated tau (ptau), a key intermediate that drives the amyloid-to-tauopathy transition, or alternatively by increased ptau-driven tau aggregation. Therefore, we investigated where along the amyloid-to-tau axis ApoE4 accelerates tau aggregation and assessed: (i) whether ApoE4 increases ptau secretion; or (ii) whether ApoE4 increases ptau-associated tau aggregation. To this end, we analysed two large-scale APOE-genotyped cohorts covering the full Alzheimer’s disease spectrum (Alzheimer’s Disease Neuroimaging Initiative; ADNI: n = 201) as well as a preclinical cohort (Anti-Amyloid Treatment in Asymptomatic Alzheimer’s and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration study; A4-LEARN: n = 200), integrating baseline amyloid-PET, plasma ptau217 and CSF ptau181 with longitudinal tau-PET. Using linear regression, we tested whether ApoE4 carriage moderates: (i) amyloid-PET-associated plasma ptau217 increases; or (ii) ptau217-associated tau spreading from local epicentres across patient-tailored tau spreading stages. All analyses were independently validated across both cohorts, including an additional replication in an ADNI subset (n = 115) with available CSF ptau181 measures as an alternative marker of ptau secretion. Finally, we used logistic regression to determine ApoE4 allele count-stratified plasma ptau217 thresholds marking early pathological tau-PET increases. We found that ApoE4 did not facilitate amyloid-PET-associated ptau increases, suggesting that amyloid-related ptau secretion is not altered by ApoE4 carriage. Contrastingly, we found that plasma ptau217 elevations were linked to faster tau-PET spread from local epicentres across connected brain regions in an ApoE4 allele dose-dependent manner, independent of amyloid [ADNI/A4-LEARN: mean standardized beta (β) = 0.44/0.56, P < 0.001/P < 0.001]. Lastly, we found that a higher ApoE4 allele count was linked to lower ptau217 thresholds marking transition to tauopathy, i.e. early abnormal tau-PET increases, consistently across both samples (ADNI: 0/1/2 ApoE4 alleles = 0.62/0.34/0.15 pg/ml, representing ∼45% and ∼76% reductions from non-carriers; Fujirebio ptau217 assay; A4-LEARN: 0/1/2 ApoE4 alleles = 0.31/0.23/0.18 pg/ml, representing ∼26% and ∼42% reductions; Eli Lilly ptau217 assay). These findings suggest that ApoE4, i.e. the key genetic risk factor for sporadic Alzheimer’s disease, facilitates amyloid-dependent tau aggregation in an allele dose-dependent manner by enhancing the ptau-driven spread of fibrillar tau, leading to an earlier transition from amyloidosis to tauopathy at lower ptau217 levels. This has implications for plasma ptau-based screening approaches and therapeutic timing of anti-amyloid drugs in ApoE4 carriers. Specifically, ApoE4 carriers may require genotype-adjusted ptau thresholds to detect Alzheimer’s disease pathophysiology, as well as anti-amyloid treatment at lower ptau levels to prevent the transition to tauopathy, which ultimately drives neurodegeneration and cognitive decline.
- Open Access
- 22 October 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (10) , e70783
A systematic comparison of ATN biomarkers for monitoring longitudinal cognitive changes in Alzheimer's disease
INTRODUCTION: With anti‐amyloid beta (Aβ) therapies approved for Alzheimer's disease (AD), surrogate biomarkers are needed to monitor clinical treatment efficacy. Therefore, we systematically compared longitudinal changes in A/T/N biomarkers (amyloid‐positron emission tomography [PET], tau‐PET, plasma phosphorylated tau at threonine 217 [p‐tau 217 ], and magnetic resonance imaging) for tracking cognitive changes. METHODS: We analyzed longitudinal biomarker and cognitive change rates from the Alzheimer's Disease Neuroimaging Initiative ( N = 141) and Anti‐Amyloid Treatment in Asymptomatic Alzheimer's (A4) and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) ( N = 151), estimated using linear mixed models. Using linear models, we tested biomarker changes as predictors of cognitive changes, comparing predictive strengths across biomarkers using bootstrapping. RESULTS: Tau‐PET, plasma p‐tau217, and cortical thickness changes accurately tracked change rates in Mini‐Mental State Examination, Alzheimer's Disease Assessment Scale‐Cognitive Subscale 13‐item version, Clinical Dementia Rating‐Sum of Boxes, and Preclinial Alzheimer Cognitive Composite scores. In contrast, amyloid‐PET change rates were not linked to cognitive changes. DISCUSSION: Plasma p‐tau 217 offers a cost‐effective AD‐specific alternative to tau‐PET and could potentially be implemented for monitoring cognitive changes in AD trials, while amyloid‐PET lacks utility. Cortical thickness changes accurately track cognitive changes but may be confounded by pseudo‐atrophy in anti‐Aβ treatments. Highlights: Longitudinal changes in tau‐PET, plasma p‐tau 217 , cortical thickness – but not amyloid‐PET – effectively track cognitive decline. Cortical thickness may be confounded by pseudo‐atrophy in anti‐Aβ trials. Plasma p‐tau 217 is a robust and cost‐effective alternative to tau‐PET as an AD‐specific surrogate biomarker for monitoring cognitive changes.
- 22 October 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (10) , e70783
Open AccessA systematic comparison of ATN biomarkers for monitoring longitudinal cognitive changes in Alzheimer's disease
INTRODUCTION: With anti‐amyloid beta (Aβ) therapies approved for Alzheimer's disease (AD), surrogate biomarkers are needed to monitor clinical treatment efficacy. Therefore, we systematically compared longitudinal changes in A/T/N biomarkers (amyloid‐positron emission tomography [PET], tau‐PET, plasma phosphorylated tau at threonine 217 [p‐tau 217 ], and magnetic resonance imaging) for tracking cognitive changes. METHODS: We analyzed longitudinal biomarker and cognitive change rates from the Alzheimer's Disease Neuroimaging Initiative ( N = 141) and Anti‐Amyloid Treatment in Asymptomatic Alzheimer's (A4) and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) ( N = 151), estimated using linear mixed models. Using linear models, we tested biomarker changes as predictors of cognitive changes, comparing predictive strengths across biomarkers using bootstrapping. RESULTS: Tau‐PET, plasma p‐tau217, and cortical thickness changes accurately tracked change rates in Mini‐Mental State Examination, Alzheimer's Disease Assessment Scale‐Cognitive Subscale 13‐item version, Clinical Dementia Rating‐Sum of Boxes, and Preclinial Alzheimer Cognitive Composite scores. In contrast, amyloid‐PET change rates were not linked to cognitive changes. DISCUSSION: Plasma p‐tau 217 offers a cost‐effective AD‐specific alternative to tau‐PET and could potentially be implemented for monitoring cognitive changes in AD trials, while amyloid‐PET lacks utility. Cortical thickness changes accurately track cognitive changes but may be confounded by pseudo‐atrophy in anti‐Aβ treatments. Highlights: Longitudinal changes in tau‐PET, plasma p‐tau 217 , cortical thickness – but not amyloid‐PET – effectively track cognitive decline. Cortical thickness may be confounded by pseudo‐atrophy in anti‐Aβ trials. Plasma p‐tau 217 is a robust and cost‐effective alternative to tau‐PET as an AD‐specific surrogate biomarker for monitoring cognitive changes.
- Top Cited Papers
- 22 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (782) , eadp2564
Amyloid-associated hyperconnectivity drives tau spread across connected brain regions in Alzheimer’s disease
In Alzheimer’s disease (AD), amyloid-β (Aβ) triggers the aggregation and spreading of tau pathology, which drives neurodegeneration and cognitive decline. However, the pathophysiological link between Aβ and tau remains unclear, which hinders therapeutic efforts to attenuate Aβ-related tau accumulation. Aβ has been found to trigger neuronal hyperactivity and hyperconnectivity, and preclinical research has shown that tau spreads across connected neurons in an activity-dependent manner. Here, we hypothesized that neuronal hyperactivity and hypersynchronicity, resulting in functional connectivity increases, constitute a crucial mechanism by which Aβ facilitates the spreading of tau pathology. By combining Aβ positron emission tomography (PET), resting-state functional magnetic resonance imaging, and longitudinal tau-PET in 69 cognitively normal amyloid-negative controls and 140 amyloid-positive patients covering the AD spectrum, we confirmed that Aβ induces hyperconnectivity of temporal lobe tau epicenters to posterior brain regions that are vulnerable to tau accumulation in AD. This was replicated in an independent sample of 55 controls and 345 individuals with preclinical AD and low cortical tau-PET uptake, suggesting that the emergence of Aβ-related hyperconnectivity precedes neocortical tau spreading . Last, using longitudinal tau-PET and mediation analysis, we confirmed that these Aβ-related connectivity increases in tau epicenters to typical tau-vulnerable brain regions in AD mediated the effect of Aβ on faster tau accumulation, unveiling increased connectivity as a potential causal link between the two AD hallmark pathologies. Together, these findings suggest that Aβ promotes tau spreading by eliciting neuronal hyperconnectivity and that targeting Aβ-related neuronal hyperconnectivity may attenuate tau spreading in AD.
- 22 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (782) , eadp2564
Top Cited PapersAmyloid-associated hyperconnectivity drives tau spread across connected brain regions in Alzheimer’s disease
In Alzheimer’s disease (AD), amyloid-β (Aβ) triggers the aggregation and spreading of tau pathology, which drives neurodegeneration and cognitive decline. However, the pathophysiological link between Aβ and tau remains unclear, which hinders therapeutic efforts to attenuate Aβ-related tau accumulation. Aβ has been found to trigger neuronal hyperactivity and hyperconnectivity, and preclinical research has shown that tau spreads across connected neurons in an activity-dependent manner. Here, we hypothesized that neuronal hyperactivity and hypersynchronicity, resulting in functional connectivity increases, constitute a crucial mechanism by which Aβ facilitates the spreading of tau pathology. By combining Aβ positron emission tomography (PET), resting-state functional magnetic resonance imaging, and longitudinal tau-PET in 69 cognitively normal amyloid-negative controls and 140 amyloid-positive patients covering the AD spectrum, we confirmed that Aβ induces hyperconnectivity of temporal lobe tau epicenters to posterior brain regions that are vulnerable to tau accumulation in AD. This was replicated in an independent sample of 55 controls and 345 individuals with preclinical AD and low cortical tau-PET uptake, suggesting that the emergence of Aβ-related hyperconnectivity precedes neocortical tau spreading . Last, using longitudinal tau-PET and mediation analysis, we confirmed that these Aβ-related connectivity increases in tau epicenters to typical tau-vulnerable brain regions in AD mediated the effect of Aβ on faster tau accumulation, unveiling increased connectivity as a potential causal link between the two AD hallmark pathologies. Together, these findings suggest that Aβ promotes tau spreading by eliciting neuronal hyperconnectivity and that targeting Aβ-related neuronal hyperconnectivity may attenuate tau spreading in AD.
- Open Access
- 10 January 2025
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 17 (2) , 235-248
Female sex is linked to a stronger association between sTREM2 and CSF p-tau in Alzheimer’s disease
In Alzheimer’s disease (AD), Aβ triggers p-tau secretion, which drives tau aggregation. Therefore, it is critical to characterize modulators of Aβ-related p-tau increases which may alter AD trajectories. Here, we assessed whether factors known to alter tau levels in AD modulate the association between fibrillar Aβ and secreted p-tau 181 determined in the cerebrospinal fluid (CSF). To assess potentially modulating effects of female sex, younger age, and ApoE4, we included 322 ADNI participants with cross-sectional/longitudinal p-tau 181 . To determine effects of microglial activation on p-tau 181 , we included 454 subjects with cross-sectional CSF sTREM2. Running ANCOVAs for nominal and linear regressions for metric variables, we found that women had higher Aβ-related p-tau 181 levels. Higher sTREM2 was associated with elevated p-tau 181 , with stronger associations in women. Similarly, ApoE4 was related to higher p-tau 181 levels and faster p-tau 181 increases, with stronger effects in female ApoE4 carriers. Our results show that sex alone modulates the Aβ to p-tau axis, where women show higher Aβ-dependent p-tau secretion, potentially driven by elevated sTREM2-related microglial activation and stronger effects of ApoE4 carriership in women.
- 10 January 2025
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 17 (2) , 235-248
Open AccessFemale sex is linked to a stronger association between sTREM2 and CSF p-tau in Alzheimer’s disease
In Alzheimer’s disease (AD), Aβ triggers p-tau secretion, which drives tau aggregation. Therefore, it is critical to characterize modulators of Aβ-related p-tau increases which may alter AD trajectories. Here, we assessed whether factors known to alter tau levels in AD modulate the association between fibrillar Aβ and secreted p-tau 181 determined in the cerebrospinal fluid (CSF). To assess potentially modulating effects of female sex, younger age, and ApoE4, we included 322 ADNI participants with cross-sectional/longitudinal p-tau 181 . To determine effects of microglial activation on p-tau 181 , we included 454 subjects with cross-sectional CSF sTREM2. Running ANCOVAs for nominal and linear regressions for metric variables, we found that women had higher Aβ-related p-tau 181 levels. Higher sTREM2 was associated with elevated p-tau 181 , with stronger associations in women. Similarly, ApoE4 was related to higher p-tau 181 levels and faster p-tau 181 increases, with stronger effects in female ApoE4 carriers. Our results show that sex alone modulates the Aβ to p-tau axis, where women show higher Aβ-dependent p-tau secretion, potentially driven by elevated sTREM2-related microglial activation and stronger effects of ApoE4 carriership in women.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S16)
ADPrep ‐ A fully automated Alzheimer’s Disease Neuroimaging Preprocessing Pipeline for MRI and multi‐tracer PET data
Background: State‐of‐the‐art preprocessing of MRI and PET data is crucial for Alzheimer’s disease (AD) neuroimaging research. Therefore, standardization and harmonization of neuroimaging preprocessing across sites is key to generate comparable and sharable datasets and to reduce potential bias introduced by different preprocessing strategies. Further, neuroimaging preprocessing requires strong expertise in different programming languages (R/MATLAB/Python/Bash) and software packages (SPM/FSL/AFNI/FreeSurfer), i.e., a major barrier for non‐expert users. Therefore, we developed a docker‐based, state‐of‐the‐art, fully automated, neuroimaging toolbox that integrates robust preprocessing of structural/functional MRI, and multi‐tracer PET (amyloid/tau/FDG/TSPO), generating easy to use spreadsheet and nifti outputs. The toolbox requires no programming expertise and can facilitate neuroimaging analyses, data harmonization and sharing across the AD neuroimaging community.Methods: The pipeline works on standardized bids‐formatted data and was fully developed in nipype (see Figure 1). Preprocessing for structural MRI includes volumetric and cortical thickness assessments for widely used brain atlases (Desikan‐Killiany/Schaefer/LPBA/Hammers/Neuromorphometrics/Cobra/Destrieux), plus spatially normalized and smoothed grey/white‐matter segments for voxel‐based morphometry and generation of subject‐specific PET‐reference regions. Functional MRI processing includes slice‐timing and motion correction, nuisance regression, spatial normalization, and functional connectivity assessments for the above‐mentioned atlases. PET processing includes generation of spatially normalized SUVR images for different tracer‐specific reference regions, as well as extraction of atlas‐based SUVRs (PVE and non‐PVE‐corrected). Standardized imaging outputs in FreeSurfer space were benchmarked against available ADNI data to illustrate comparability with existing pipelines (see Figure 2). Cluster implementation is provided to ensure large‐scale data processing.Results: The toolbox was tested successfully on large‐scale multimodal datasets, including several thousand scans from ADNI, ADNI‐DOD, and A4 with an overall processing failure rate of <4%. Using ADNI data as a benchmark, our data closely reproduce global amyloid‐PET (r = 0.99, p<0.001, Fig.2A) and temporal meta tau‐PET SUVRs (r = 0.98, p<0.001, Fig.2B), suggesting that PET‐thresholds can be applied. Runtime is ∼1h for a structural MRI and ∼5hrs for a PET including PVE‐correction.Conclusions: We propose a user‐friendly multimodal robust neuroimaging preprocessing toolbox, that can be applied to different neuroimaging datasets by non‐expert users. The toolbox provides outputs that can be directly used for statistical analyses. Future work involves implementing other imaging modalities, e.g., diffusion tensor imaging.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S16)
Open AccessADPrep ‐ A fully automated Alzheimer’s Disease Neuroimaging Preprocessing Pipeline for MRI and multi‐tracer PET data
Background: State‐of‐the‐art preprocessing of MRI and PET data is crucial for Alzheimer’s disease (AD) neuroimaging research. Therefore, standardization and harmonization of neuroimaging preprocessing across sites is key to generate comparable and sharable datasets and to reduce potential bias introduced by different preprocessing strategies. Further, neuroimaging preprocessing requires strong expertise in different programming languages (R/MATLAB/Python/Bash) and software packages (SPM/FSL/AFNI/FreeSurfer), i.e., a major barrier for non‐expert users. Therefore, we developed a docker‐based, state‐of‐the‐art, fully automated, neuroimaging toolbox that integrates robust preprocessing of structural/functional MRI, and multi‐tracer PET (amyloid/tau/FDG/TSPO), generating easy to use spreadsheet and nifti outputs. The toolbox requires no programming expertise and can facilitate neuroimaging analyses, data harmonization and sharing across the AD neuroimaging community.Methods: The pipeline works on standardized bids‐formatted data and was fully developed in nipype (see Figure 1). Preprocessing for structural MRI includes volumetric and cortical thickness assessments for widely used brain atlases (Desikan‐Killiany/Schaefer/LPBA/Hammers/Neuromorphometrics/Cobra/Destrieux), plus spatially normalized and smoothed grey/white‐matter segments for voxel‐based morphometry and generation of subject‐specific PET‐reference regions. Functional MRI processing includes slice‐timing and motion correction, nuisance regression, spatial normalization, and functional connectivity assessments for the above‐mentioned atlases. PET processing includes generation of spatially normalized SUVR images for different tracer‐specific reference regions, as well as extraction of atlas‐based SUVRs (PVE and non‐PVE‐corrected). Standardized imaging outputs in FreeSurfer space were benchmarked against available ADNI data to illustrate comparability with existing pipelines (see Figure 2). Cluster implementation is provided to ensure large‐scale data processing.Results: The toolbox was tested successfully on large‐scale multimodal datasets, including several thousand scans from ADNI, ADNI‐DOD, and A4 with an overall processing failure rate of <4%. Using ADNI data as a benchmark, our data closely reproduce global amyloid‐PET (r = 0.99, p<0.001, Fig.2A) and temporal meta tau‐PET SUVRs (r = 0.98, p<0.001, Fig.2B), suggesting that PET‐thresholds can be applied. Runtime is ∼1h for a structural MRI and ∼5hrs for a PET including PVE‐correction.Conclusions: We propose a user‐friendly multimodal robust neuroimaging preprocessing toolbox, that can be applied to different neuroimaging datasets by non‐expert users. The toolbox provides outputs that can be directly used for statistical analyses. Future work involves implementing other imaging modalities, e.g., diffusion tensor imaging.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S16)
Increased CSF GAP‐43 is associated with accelerated tau accumulation and spread in Alzheimer’s disease
Background: Animal and in vitro studies of Alzheimer’s disease (AD) found that tau spreads trans‐synaptically in an activity‐dependent manner, suggesting that synapses are key routes for tau spread. Importantly, amyloid‐beta (Ab) induces synaptic remodeling and aberrant synaptic activity, which may accelerate trans‐synaptic tau spread. In AD patients, we found previously that PET‐assessed tau spreads from circumscribed epicenters across functionally connected brain regions. Yet, it remains unclear whether connectivity‐associated spread of tau in AD is accelerated by Ab‐related synaptic changes. The presynaptic growth‐associated protein 43 (GAP‐43) is implicated in synaptic plasticity and is consistently increased in cerebrospinal fluid (CSF) in AD, suggesting that GAP‐43 captures deviations in synaptic integrity such as aberrant synaptic activity. We therefore tested whether higher GAP‐43 is associated with faster Ab‐related tau spread.Methods: We included longitudinal [18F]Flortaucipir tau‐PET (follow‐up∼3.21±1.48yrs), baseline [18F]Florbetapir amyloid‐PET and CSF GAP‐43 from 93 subjects (i.e., cognitively normal [CN] controls Ab‐, n = 54; CN/Mild Cognitive Impairment Ab+, n = 33/21). To model connectivity‐associated tau spread, we determined a connectivity template across 200 cortical regions (i.e., Schaefer atlas) using 3T multi‐band resting‐state fMRI in 42 age‐ and sex‐matched Ab‐/tau‐ controls. All statistical models were controlled for age, sex and diagnosis.Results: Using linear regression, we found that higher CSF GAP‐43 levels were associated with faster Ab‐related tau‐PET increase in pre‐defined ROIs (centiloid x GAP‐43 interaction, global/temporal‐meta‐ROI: b = 0.0019/0.0028; p = 0.009/0.007, Fig.1) as well as in the personalized Q1 ROI (b = 0.0024; p = 0.004) that summarizes regions most closely connected to subject‐specific tau epicenters with highest baseline tau‐PET (Fig.2A). Importantly, this centiloid x GAP‐43 interaction decreased across regions less strongly connected to tau epicenters (Q2/Q3/Q4: b = 0.0017/0.0008/0.0002; p = 0.009/0.080/0.344, Fig.2B‐D, 3A). Further, we quantified subject‐specific connectivity‐associated tau spread (i.e., the regression‐derived association between epicenter connectivity and tau‐PET increase in remaining brain regions). Here, higher CSF GAP‐43 was associated with a stronger association between Ab and connectivity‐associated tau spread (centiloid x GAP‐43 interaction, b = ‐0.0031; p = 0.037, Fig.3B).Conclusions: Higher CSF GAP‐43 is associated with faster Ab‐related tau spread across interconnected brain regions in AD, suggesting that AD‐related synaptic abnormalities are associated with accelerated tau spread rendering synaptic changes a potential treatment target to attenuate tau spreading.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S16)
Open AccessIncreased CSF GAP‐43 is associated with accelerated tau accumulation and spread in Alzheimer’s disease
Background: Animal and in vitro studies of Alzheimer’s disease (AD) found that tau spreads trans‐synaptically in an activity‐dependent manner, suggesting that synapses are key routes for tau spread. Importantly, amyloid‐beta (Ab) induces synaptic remodeling and aberrant synaptic activity, which may accelerate trans‐synaptic tau spread. In AD patients, we found previously that PET‐assessed tau spreads from circumscribed epicenters across functionally connected brain regions. Yet, it remains unclear whether connectivity‐associated spread of tau in AD is accelerated by Ab‐related synaptic changes. The presynaptic growth‐associated protein 43 (GAP‐43) is implicated in synaptic plasticity and is consistently increased in cerebrospinal fluid (CSF) in AD, suggesting that GAP‐43 captures deviations in synaptic integrity such as aberrant synaptic activity. We therefore tested whether higher GAP‐43 is associated with faster Ab‐related tau spread.Methods: We included longitudinal [18F]Flortaucipir tau‐PET (follow‐up∼3.21±1.48yrs), baseline [18F]Florbetapir amyloid‐PET and CSF GAP‐43 from 93 subjects (i.e., cognitively normal [CN] controls Ab‐, n = 54; CN/Mild Cognitive Impairment Ab+, n = 33/21). To model connectivity‐associated tau spread, we determined a connectivity template across 200 cortical regions (i.e., Schaefer atlas) using 3T multi‐band resting‐state fMRI in 42 age‐ and sex‐matched Ab‐/tau‐ controls. All statistical models were controlled for age, sex and diagnosis.Results: Using linear regression, we found that higher CSF GAP‐43 levels were associated with faster Ab‐related tau‐PET increase in pre‐defined ROIs (centiloid x GAP‐43 interaction, global/temporal‐meta‐ROI: b = 0.0019/0.0028; p = 0.009/0.007, Fig.1) as well as in the personalized Q1 ROI (b = 0.0024; p = 0.004) that summarizes regions most closely connected to subject‐specific tau epicenters with highest baseline tau‐PET (Fig.2A). Importantly, this centiloid x GAP‐43 interaction decreased across regions less strongly connected to tau epicenters (Q2/Q3/Q4: b = 0.0017/0.0008/0.0002; p = 0.009/0.080/0.344, Fig.2B‐D, 3A). Further, we quantified subject‐specific connectivity‐associated tau spread (i.e., the regression‐derived association between epicenter connectivity and tau‐PET increase in remaining brain regions). Here, higher CSF GAP‐43 was associated with a stronger association between Ab and connectivity‐associated tau spread (centiloid x GAP‐43 interaction, b = ‐0.0031; p = 0.037, Fig.3B).Conclusions: Higher CSF GAP‐43 is associated with faster Ab‐related tau spread across interconnected brain regions in AD, suggesting that AD‐related synaptic abnormalities are associated with accelerated tau spread rendering synaptic changes a potential treatment target to attenuate tau spreading.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S17)
APOEε4 facilitates the accumulation and connectivity‐mediated spreading of tau pathology at lower amyloid levels
Background: Targeting amyloid (Aß) may show highest clinical efficacy when preventing downstream tau spreading and subsequent neurodegeneration. Thus, it’s critical to establish Aß‐PET thresholds at which tau spreading is triggered, which may depend on ApoE4, i.e. a key genetic risk factor for Aß, tau and cognitive decline. Yet, ApoE4’s impact on Aß‐related tau spreading is unclear, which may bias intervention studies. Thus, we assessed whether ApoE4‐carriage facilitates Aß‐associated tau spreading and determined thresholds at which Aß‐related tau trajectories diverge between ApoE4‐carriers vs. non‐carriers. Lastly, we ran simulated trials using tau‐PET endpoints to test whether including ApoE4‐carriers increases the sensitivity to detect treatment effects at lower Aß‐levels.Method: We included non‐demented ADNI subjects (n = 237), and a replication sample (18F‐AV‐1451‐A05 trial, n = 130). We combined ApoE4‐status, amyloid‐PET and longitudinal flortaucipir tau‐PET alongside resting‐state fMRI‐connectivity templates from n = 42 Aß‐ controls to assess connectivity‐based tau spreading (subject‐specific tau epicentre connectivity ranked regions i.e. Q1‐Q4) together with tau accumulation in Braak‐stage specific regions. We used i) mediation models to test whether ApoE4 effects on Braak‐stage specific tau accumulation were mediated by centiloid and ii) linear models to determine the centiloid by ApoE4 interaction on tau accumulation in Q1‐Q4 and Braak‐stage regions and iii) determined confidence interval‐based cut‐points of ApoE4‐related divergence in tau trajectories. Lastly, we estimated ApoE4‐stratified sample sizes to detect simulated treatments effects on tau accumulation across increasing centiloid windows.Result: Using bootstrapped mediation we found that centiloid mediated faster ApoE4‐related tau‐PET increase in early Braak‐stage regions (ADNI/A05, BraakIII: B = 0.19/0.33, p<0.001/<0.001), and that ApoE4 facilitates Aß‐related tau spreading (ApoE4*centiloid interaction on tau‐PET increase) in early Braak‐stage and connectivity‐based ROIs. We identified centiloid cut‐points (∼10‐15) where Aß‐related tau accumulation rates diverged between ApoE4 carriers vs. non‐carriers through Braak and connectivity stages (Fig.1), which replicated across samples. Lastly, focusing on ApoE4‐carriers exclusively in simulated clinical trials increased the sensitivity for detecting treatment effects on tau accumulation at lower centiloid levels (Fig.2).Conclusion: ApoE4 is related to earlier Aß‐related tau accumulation, which may drive faster ApoE4‐related disease progression. Our results are relevant for clinical trial design, illustrating that ApoE4‐carriers may require earlier anti‐Aß intervention to attenuate downstream tau spreading.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S17)
Open AccessAPOEε4 facilitates the accumulation and connectivity‐mediated spreading of tau pathology at lower amyloid levels
Background: Targeting amyloid (Aß) may show highest clinical efficacy when preventing downstream tau spreading and subsequent neurodegeneration. Thus, it’s critical to establish Aß‐PET thresholds at which tau spreading is triggered, which may depend on ApoE4, i.e. a key genetic risk factor for Aß, tau and cognitive decline. Yet, ApoE4’s impact on Aß‐related tau spreading is unclear, which may bias intervention studies. Thus, we assessed whether ApoE4‐carriage facilitates Aß‐associated tau spreading and determined thresholds at which Aß‐related tau trajectories diverge between ApoE4‐carriers vs. non‐carriers. Lastly, we ran simulated trials using tau‐PET endpoints to test whether including ApoE4‐carriers increases the sensitivity to detect treatment effects at lower Aß‐levels.Method: We included non‐demented ADNI subjects (n = 237), and a replication sample (18F‐AV‐1451‐A05 trial, n = 130). We combined ApoE4‐status, amyloid‐PET and longitudinal flortaucipir tau‐PET alongside resting‐state fMRI‐connectivity templates from n = 42 Aß‐ controls to assess connectivity‐based tau spreading (subject‐specific tau epicentre connectivity ranked regions i.e. Q1‐Q4) together with tau accumulation in Braak‐stage specific regions. We used i) mediation models to test whether ApoE4 effects on Braak‐stage specific tau accumulation were mediated by centiloid and ii) linear models to determine the centiloid by ApoE4 interaction on tau accumulation in Q1‐Q4 and Braak‐stage regions and iii) determined confidence interval‐based cut‐points of ApoE4‐related divergence in tau trajectories. Lastly, we estimated ApoE4‐stratified sample sizes to detect simulated treatments effects on tau accumulation across increasing centiloid windows.Result: Using bootstrapped mediation we found that centiloid mediated faster ApoE4‐related tau‐PET increase in early Braak‐stage regions (ADNI/A05, BraakIII: B = 0.19/0.33, p<0.001/<0.001), and that ApoE4 facilitates Aß‐related tau spreading (ApoE4*centiloid interaction on tau‐PET increase) in early Braak‐stage and connectivity‐based ROIs. We identified centiloid cut‐points (∼10‐15) where Aß‐related tau accumulation rates diverged between ApoE4 carriers vs. non‐carriers through Braak and connectivity stages (Fig.1), which replicated across samples. Lastly, focusing on ApoE4‐carriers exclusively in simulated clinical trials increased the sensitivity for detecting treatment effects on tau accumulation at lower centiloid levels (Fig.2).Conclusion: ApoE4 is related to earlier Aß‐related tau accumulation, which may drive faster ApoE4‐related disease progression. Our results are relevant for clinical trial design, illustrating that ApoE4‐carriers may require earlier anti‐Aß intervention to attenuate downstream tau spreading.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S17)
The effect of local versus remote Beta‐Amyloid on functional connectivity mediated Tau‐Spread in Alzheimer’s Disease
Background: In Alzheimer’s disease (AD), Amyloid‐beta deposition (Ab) is associated with tau spreading from epicenters to connected regions. Yet, Ab and tau accumulate in strikingly different patterns, and it is unclear how Abdrives tau spreading. We envision two mechanisms, i.e. i) that cortical Ab exerts remote effects and “pulls” tau out of connected epicenters or ii) that tau is pushed out of epicenters, once Ab has reached the tau epicenters (Fig.1A). We tested both mechanisms in AD spectrum patients and determined the predominant mechanism by which Ab drives tau spreading.Methods: We included 313 ADNI participants (n = 110 CN Ab‐, n = 98 CN‐Ab+, n = 70 MCI Ab+, n = 35 Dementia Ab+), with baseline amyloid‐ and longitudinal tau‐PET, based on which we calculated tau‐PET rates of change (ROC) for 200 cortical ROIs (Schaefer‐atlas; Fig.2). Using the same atlas, a resting‐state fMRI‐connectivity template was obtained in 42 healthy controls. For each subject, we determined tau epicenters as 5% of ROIs with highest baseline tau‐PET and assessed epicenter connectivity. Using ROI‐wise regression, we tested whether faster tau‐PET increase was explained by the simultaneous occurrence of i) higher tau‐PET in the epicenter, ii) stronger connectivity to the tau epicenter and iii) higher Ab in the target region (i.e. pull‐effect) or the tau epicenter (i.e. push‐effect). Lastly, we assessed ROI‐wise main effects of local Ab vs. Ab in the tau epicenter on tau‐PET changes, to determine which mechanism predominates.Results: Higher tau and Ab in the epicenter explained faster tau‐PET increase in connected temporo‐parietal and frontal regions (Ab‐push‐effect, Fig.1B). In contrast, Ab‐pull‐effects were found also for late‐Braak regions (Fig.1C). Congruently, we found that Ab push effects dominated over Ab‐pull effects in temporo‐parietal brain regions, whereas Ab‐pull effects dominated in late‐Braak regions (Fig.1D‐F). Lastly, patients in which Ab and tau converged locally showed fastest subsequent tau accumulation (Fig.3).Conclusion: Ab exerts local and remote effects on tau spreading, yet local convergence of Ab and tau in the epicenter may predominantly drive tau spreading. Thus, local convergence of Ab and tau is a key event in AD that gives rise to accelerated tau spreading, previously referred to as cataustrophy.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S17)
Open AccessThe effect of local versus remote Beta‐Amyloid on functional connectivity mediated Tau‐Spread in Alzheimer’s Disease
Background: In Alzheimer’s disease (AD), Amyloid‐beta deposition (Ab) is associated with tau spreading from epicenters to connected regions. Yet, Ab and tau accumulate in strikingly different patterns, and it is unclear how Abdrives tau spreading. We envision two mechanisms, i.e. i) that cortical Ab exerts remote effects and “pulls” tau out of connected epicenters or ii) that tau is pushed out of epicenters, once Ab has reached the tau epicenters (Fig.1A). We tested both mechanisms in AD spectrum patients and determined the predominant mechanism by which Ab drives tau spreading.Methods: We included 313 ADNI participants (n = 110 CN Ab‐, n = 98 CN‐Ab+, n = 70 MCI Ab+, n = 35 Dementia Ab+), with baseline amyloid‐ and longitudinal tau‐PET, based on which we calculated tau‐PET rates of change (ROC) for 200 cortical ROIs (Schaefer‐atlas; Fig.2). Using the same atlas, a resting‐state fMRI‐connectivity template was obtained in 42 healthy controls. For each subject, we determined tau epicenters as 5% of ROIs with highest baseline tau‐PET and assessed epicenter connectivity. Using ROI‐wise regression, we tested whether faster tau‐PET increase was explained by the simultaneous occurrence of i) higher tau‐PET in the epicenter, ii) stronger connectivity to the tau epicenter and iii) higher Ab in the target region (i.e. pull‐effect) or the tau epicenter (i.e. push‐effect). Lastly, we assessed ROI‐wise main effects of local Ab vs. Ab in the tau epicenter on tau‐PET changes, to determine which mechanism predominates.Results: Higher tau and Ab in the epicenter explained faster tau‐PET increase in connected temporo‐parietal and frontal regions (Ab‐push‐effect, Fig.1B). In contrast, Ab‐pull‐effects were found also for late‐Braak regions (Fig.1C). Congruently, we found that Ab push effects dominated over Ab‐pull effects in temporo‐parietal brain regions, whereas Ab‐pull effects dominated in late‐Braak regions (Fig.1D‐F). Lastly, patients in which Ab and tau converged locally showed fastest subsequent tau accumulation (Fig.3).Conclusion: Ab exerts local and remote effects on tau spreading, yet local convergence of Ab and tau in the epicenter may predominantly drive tau spreading. Thus, local convergence of Ab and tau is a key event in AD that gives rise to accelerated tau spreading, previously referred to as cataustrophy.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S16)
Effects of cerebrovascular disease on tau progression and cognitive decline in Alzheimer’s disease
Background: Recent post‐mortem studies suggest that cerebrovascular disease contributes to Alzheimer’s disease (AD) pathophysiology and clinical progression. In particular, cerebral amyloid angiopathy is highly common in AD and has been linked to faster cognitive decline. Yet, in‐vivo evidence on the contribution of cerebrovascular disease to pathobiological and/or clinical AD progression is rare. Thus, we assessed in‐vivo, whether i) higher cerebrovascular burden is associated with accelerated progression of primary AD pathology and ii) whether cerebrovascular burden synergistically accelerates AD‐related cognitive decline.Method: We included n = 256 participants from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) across the AD spectrum with longitudinal 18F‐flortaucipir tau‐PET (follow‐up∼2.30±1.32 years), 18F‐florbetapir or 18F‐florbetaben Aβ‐PET transformed to centiloid (Aβ–: n = 85 Cognitively normal (CN); Aβ+: n = 83 CN, n = 57 Mild Cognitive Impairment, n = 31 Dementia). We focused on global white matter hyperintensity (WMH) volume adjusted to intracranial volume and microhemorrhage (MCH) count as well‐established cerebrovascular disease markers. Cognition was probed through the AD Assessment Scale Cognition 13‐item scale (ADAS‐13). Subject‐specific annual changes in tau‐PET and cognition were calculated via linear mixed models, including random slope and intercept. To enhance reproducibility of our findings, statistical analyses were pre‐specified at AsPredicted.org. All statistical models were controlled for age, sex and APOE.Result: Using linear regression, we found no main effect of cerebrovascular disease markers on baseline amyloid‐PET or tau‐PET (ps>0.05). Further, higher cerebrovascular burden was not associated with faster Aβ‐related tau‐PET SUVR increase (Fig. 1A+B). In contrast, higher cerebrovascular burden was associated with accelerated cognitive decline. Specifically, interaction models revealed that a higher MCH count was associated with faster cognitive decline at higher tau levels (Fig. 1C), while higher white matter hyperintensity burden was associated with faster cognitive decline at lower tau levels (Fig. 1D).Conclusion: We found no effect of cerebrovascular disease on primary AD pathology. In contrast, cerebrovascular disease was linked to accelerated tau‐associated cognitive decline. This suggests that cerebrovascular disease may not modulate pathobiological AD trajectories but rather add synergistically to AD symptom severity. This has important therapeutic implications, as treating cerebrovascular disease in addition to primary AD pathology (e.g. amyloid) may yield largest clinical efficacy.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S16)
Open AccessEffects of cerebrovascular disease on tau progression and cognitive decline in Alzheimer’s disease
Background: Recent post‐mortem studies suggest that cerebrovascular disease contributes to Alzheimer’s disease (AD) pathophysiology and clinical progression. In particular, cerebral amyloid angiopathy is highly common in AD and has been linked to faster cognitive decline. Yet, in‐vivo evidence on the contribution of cerebrovascular disease to pathobiological and/or clinical AD progression is rare. Thus, we assessed in‐vivo, whether i) higher cerebrovascular burden is associated with accelerated progression of primary AD pathology and ii) whether cerebrovascular burden synergistically accelerates AD‐related cognitive decline.Method: We included n = 256 participants from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) across the AD spectrum with longitudinal 18F‐flortaucipir tau‐PET (follow‐up∼2.30±1.32 years), 18F‐florbetapir or 18F‐florbetaben Aβ‐PET transformed to centiloid (Aβ–: n = 85 Cognitively normal (CN); Aβ+: n = 83 CN, n = 57 Mild Cognitive Impairment, n = 31 Dementia). We focused on global white matter hyperintensity (WMH) volume adjusted to intracranial volume and microhemorrhage (MCH) count as well‐established cerebrovascular disease markers. Cognition was probed through the AD Assessment Scale Cognition 13‐item scale (ADAS‐13). Subject‐specific annual changes in tau‐PET and cognition were calculated via linear mixed models, including random slope and intercept. To enhance reproducibility of our findings, statistical analyses were pre‐specified at AsPredicted.org. All statistical models were controlled for age, sex and APOE.Result: Using linear regression, we found no main effect of cerebrovascular disease markers on baseline amyloid‐PET or tau‐PET (ps>0.05). Further, higher cerebrovascular burden was not associated with faster Aβ‐related tau‐PET SUVR increase (Fig. 1A+B). In contrast, higher cerebrovascular burden was associated with accelerated cognitive decline. Specifically, interaction models revealed that a higher MCH count was associated with faster cognitive decline at higher tau levels (Fig. 1C), while higher white matter hyperintensity burden was associated with faster cognitive decline at lower tau levels (Fig. 1D).Conclusion: We found no effect of cerebrovascular disease on primary AD pathology. In contrast, cerebrovascular disease was linked to accelerated tau‐associated cognitive decline. This suggests that cerebrovascular disease may not modulate pathobiological AD trajectories but rather add synergistically to AD symptom severity. This has important therapeutic implications, as treating cerebrovascular disease in addition to primary AD pathology (e.g. amyloid) may yield largest clinical efficacy.
- Open Access
- 24 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S10)
ADPrep ‐ A fully automated Alzheimer’s Disease Neuroimaging Preprocessing Pipeline for MRI and multi‐tracer PET data
Background: State‐of‐the‐art preprocessing of MRI and PET data is crucial for Alzheimer’s disease (AD) neuroimaging research. Therefore, standardization and harmonization of neuroimaging preprocessing across sites is key to generate comparable and sharable datasets and to reduce potential bias introduced by different preprocessing strategies. Further, neuroimaging preprocessing requires strong expertise in different programming languages (R/MATLAB/Python/Bash) and software packages (SPM/FSL/AFNI/FreeSurfer), i.e., a major barrier for non‐expert users. Therefore, we developed a docker‐based, state‐of‐the‐art, fully automated, neuroimaging toolbox that integrates robust preprocessing of structural/functional MRI, and multi‐tracer PET (amyloid/tau/FDG/TSPO), generating easy to use spreadsheet and nifti outputs. The toolbox requires no programming expertise and can facilitate neuroimaging analyses, data harmonization and sharing across the AD neuroimaging community.Method: The pipeline works on standardized bids‐formatted data and was fully developed in nipype (see Figure 1). Preprocessing for structural MRI includes volumetric and cortical thickness assessments for widely used brain atlases (Desikan‐Killiany/Schaefer/LPBA/Hammers/Neuromorphometrics/Cobra/Destrieux), plus spatially normalized and smoothed grey/white‐matter segments for voxel‐based morphometry and generation of subject‐specific PET‐reference regions. Functional MRI processing includes slice‐timing and motion correction, nuisance regression, spatial normalization, and functional connectivity assessments for the above‐mentioned atlases. PET processing includes generation of spatially normalized SUVR images for different tracer‐specific reference regions, as well as extraction of atlas‐based SUVRs (PVE and non‐PVE‐corrected). Standardized imaging outputs in FreeSurfer space were benchmarked against available ADNI data to illustrate comparability with existing pipelines (see Figure 2). Cluster implementation is provided to ensure large‐scale data processing.Result: The toolbox was tested successfully on large‐scale multimodal datasets, including several thousand scans from ADNI, ADNI‐DOD, and A4 with an overall processing failure rate of <4%. Using ADNI data as a benchmark, our data closely reproduce global amyloid‐PET (r = 0.99, p<0.001, Fig.2A) and temporal meta tau‐PET SUVRs (r = 0.98, p<0.001, Fig.2B), suggesting that PET‐thresholds can be applied. Runtime is ∼1h for a structural MRI and ∼5hrs for a PET including PVE‐correction.Conclusion: We propose a user‐friendly multimodal robust neuroimaging preprocessing toolbox, that can be applied to different neuroimaging datasets by non‐expert users. The toolbox provides outputs that can be directly used for statistical analyses. Future work involves implementing other imaging modalities, e.g., diffusion tensor imaging.
- 24 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S10)
Open AccessADPrep ‐ A fully automated Alzheimer’s Disease Neuroimaging Preprocessing Pipeline for MRI and multi‐tracer PET data
Background: State‐of‐the‐art preprocessing of MRI and PET data is crucial for Alzheimer’s disease (AD) neuroimaging research. Therefore, standardization and harmonization of neuroimaging preprocessing across sites is key to generate comparable and sharable datasets and to reduce potential bias introduced by different preprocessing strategies. Further, neuroimaging preprocessing requires strong expertise in different programming languages (R/MATLAB/Python/Bash) and software packages (SPM/FSL/AFNI/FreeSurfer), i.e., a major barrier for non‐expert users. Therefore, we developed a docker‐based, state‐of‐the‐art, fully automated, neuroimaging toolbox that integrates robust preprocessing of structural/functional MRI, and multi‐tracer PET (amyloid/tau/FDG/TSPO), generating easy to use spreadsheet and nifti outputs. The toolbox requires no programming expertise and can facilitate neuroimaging analyses, data harmonization and sharing across the AD neuroimaging community.Method: The pipeline works on standardized bids‐formatted data and was fully developed in nipype (see Figure 1). Preprocessing for structural MRI includes volumetric and cortical thickness assessments for widely used brain atlases (Desikan‐Killiany/Schaefer/LPBA/Hammers/Neuromorphometrics/Cobra/Destrieux), plus spatially normalized and smoothed grey/white‐matter segments for voxel‐based morphometry and generation of subject‐specific PET‐reference regions. Functional MRI processing includes slice‐timing and motion correction, nuisance regression, spatial normalization, and functional connectivity assessments for the above‐mentioned atlases. PET processing includes generation of spatially normalized SUVR images for different tracer‐specific reference regions, as well as extraction of atlas‐based SUVRs (PVE and non‐PVE‐corrected). Standardized imaging outputs in FreeSurfer space were benchmarked against available ADNI data to illustrate comparability with existing pipelines (see Figure 2). Cluster implementation is provided to ensure large‐scale data processing.Result: The toolbox was tested successfully on large‐scale multimodal datasets, including several thousand scans from ADNI, ADNI‐DOD, and A4 with an overall processing failure rate of <4%. Using ADNI data as a benchmark, our data closely reproduce global amyloid‐PET (r = 0.99, p<0.001, Fig.2A) and temporal meta tau‐PET SUVRs (r = 0.98, p<0.001, Fig.2B), suggesting that PET‐thresholds can be applied. Runtime is ∼1h for a structural MRI and ∼5hrs for a PET including PVE‐correction.Conclusion: We propose a user‐friendly multimodal robust neuroimaging preprocessing toolbox, that can be applied to different neuroimaging datasets by non‐expert users. The toolbox provides outputs that can be directly used for statistical analyses. Future work involves implementing other imaging modalities, e.g., diffusion tensor imaging.